Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...

The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

The electric-vehicle maker has an aging lineup and slumping sales, but its CEO has shifted his focus to robotaxis and robots. The cuts represent less than 4% of the company's global workforce and come ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...